Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/TCTR20200430002
TCTR20200430002CompletedPhase 2

A Randomized, Controlled Parallel Study to Compare Efficacy and Safety of HINE E-GEL with General Concentrated Liquid Diet with Tube Feeding †An Exploratory Study

Otsuka Pharmaceutical Factory, Inc.0 sites30 target enrollmentStarted: April 30, 2020Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions

Trial Snapshot

Phase
Phase 2
Status
Completed
Sponsor
Enrollment
30
Study OverviewEligibility CriteriaInvestigatorsRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Ages
18 Years to 0 N/A (No limit) (—)
Sex
All

Inclusion Criteria

  • •1.Patients aged 18 years or older on the date of informed consent.
  • •2.Patients already hospitalized and undergoing tube feeding with 12-16 Fr nasogastric tube or percutaneous endoscopic gastrostomy (PEG) feeding tubes, and who prospectively will be on tube feeding at least 9 days after inclusion.
  • •3.Patients who provide voluntary consent after receiving a sufficient oral and written explanation about the study. If the patient is unconscious, a patient’s legal representative may also provide consent.

Exclusion Criteria

  • •1.Patients who have a previous history of gastrectomy or other upper gastrointestinal disorders that unsuitable for inclusion in the study.
  • •2.Patients who might have food allergies or allergies to any of the products used in the study.
  • •3.Patients who receive anticancer drugs or radiotherapy.
  • •4.Patients who are deemed unsuitable for inclusion in the study due to concomitant diseases including hepatic disorder, renal disorder, and cardiac disorder.
  • •5.Others who are deemed unsuitable for inclusion in the study for any other reason based on decision by the investigator.

Investigators

Sponsor
Otsuka Pharmaceutical Factory, Inc.

Similar Trials

Recruiting
Phase 4
A Randomized Parallel Group Controlled Study between 3.75 mg of Leuprorelin and 1.8 mg of Goserelin Depot in the Sequential Therapy (GnRH Agonist + Dienogest) for Treatment of Endometriosisendometriosis, chocolate cyst or adenomyosis uteri
JPRN-UMIN000010332Tokyo Women's Medical University Department of Obstetrics and Gynecology120
Active, not recruiting
Phase 1
Randomized, parallel controlled study with routine clinical practice to evaluate the efficacy and tolerability of PRFC ENDORET® in the treatment of frontal fibrosing alopecia• Patients diagnosed with fibrosing frontal alopecia (FFA) with an age greater than or equal to 18 years.• Patient not responding to previous treatments for at least 6 months.• Use of effective physical or pharmacological contraceptive measures• Free acceptance to participate in the trial, with the written informed consent of the volunteer.
EUCTR2021-000865-33-ESINSTITUTO DE INVESTIGACIÓN SANITARIA BIOARABA74
Recruiting
Not Applicable
A randomized parallel-group controlled study for personalized postoperative pain management based on prediction of fentanyl requirements by genetic polymorphisms in patients undergoing orthognathic surgeryPain
JPRN-UMIN000006805Tokyo Metropolitan Institute of Medical Science300
Completed
Not Applicable
Bioavailability of oral curcumin ingestio
ISRCTN83602901OmniActive Health Technologies Ltd15
Completed
Not Applicable
Randomized parallel controlled trial of "on demand" therapy versus continuous therapy of omepral 20mg in effectiveness and safety for the patients {Los Angeles classification grade M (LA M) or more)} diagnosed as the gastroesophageal reflux disease.Gastroesophageal reflux disease (LA gradeM or more)
JPRN-UMIN000001937Department of Gastroenterology Juntendo University School of Medicine200